Give Your Patients An Early Advantage

NxGen’s Early Advantage Panel screens for 65 genetic conditions during or before pregnancy to give you the tools you need to provide your patients with the best care possible.

With the Early Advantage Panel, you can give your patients more pregnancy and birth plan options, shorten the diagnostic odyssey, and be ready to begin any necessary treatment right after birth.

Give Your Patients An Early Advantage

What is the Early Advantage Panel?

The Early Advantage Panel from NxGen MDx is an innovative approach to carrier screening panel design because it is the first of its size to incorporate conditions that the U.S. Department of Health and Human Services (HHS) recommends be included in newborn screening (NBS), reiterating our focus on improving pregnancy and newborn health outcomes for families everywhere.

The list of conditions that the HHS recommends all states use in their NBS programs is known as the Recommended Uniform Screening Panel (RUSP) and was compiled based on evidence that supports the benefits of early diagnosis and the availability of effective treatments.

Strengthening Newborn Screening

NBS is one of the most successful public health initiatives in the US. It is the nation’s largest genetic screening program and screens approximately 4 million infants every year. While NBS is an important part of neonatal care, it does have some limitations.

  • The number of conditions screened for is inconsistent from state to state.
  • NBS can be negatively impacted by several different factors such as birth weight, ethnicity, and time of sample collection that can lead to more false positives & false negatives.
  • Results may be returned too late to begin treatments that are critical in the first few days of life.

As a doctor, when you know a child’s risk for a genetic condition before they are born, you can work with parents to come up with a birth and early care plan supplemented by targeted diagnostic testing.

NBS in the United States

Addressing Gaps in the Newborn Screening Program

NxGen's NatalCare Philosophy

NatalCare is NxGen’s curation philosophy for our carrier screening, NIPS, vaginosis, and urinary tract infection products which focuses on improving pregnancy and newborn outcomes.

Our innovative approach in designing the Early Advantage Panel lets us detect more at-risk pregnancies, increase prenatal and birth team choices, and facilitate faster diagnoses and earlier treatments for genetic conditions.

Conditions in the Early Advantage Panel

RUSP conditions are bolded

  • 21-Hydroxylase-Deficient Congenital Adrenal Hyperplasia
  • Beta-Thalassemia
  • Bloom Syndrome
  • Canavan Disease
  • Cystic Fibrosis and CFTR-Related Disorders
  • Dihydrolipoamide Dehydrogenase Deficiency
  • DMD-Related Dystrophinopathy (Duchenne Muscular Dystrophy and Becker Muscular Dystrophy
  • Familial Dysautonomia
  • Familial Hyperinsulinism, ABCC8-Related
  • Fanconi Anemia Type C
  • Fragile X and FMR1-Related Disorders
  • FKTN-Related Disorders (Including Walker-Warburg Syndrome)
  • Gaucher Disease
  • Glycogen Storage Disease Type IA
  • Glycogen Storage Disease Type II (Pompe Disease)
  • Glycogen Storage Disease Type IV/Adilt Polyglucosan Body Disease
  • Joubert Syndrome 2/TMEM216-Related Disorders
  • Maple Syrup Urine Disease Type 1A
  • Maple Syrup Urine Disease Type 1B
  • Metachromatic Leukodystrophy, ARSA-Related
  • Mucolipidosis IV
  • Nemaline Myopathy 2
  • Niemann-Pick Disease Type A/B
  • SLC26A2-Related Disorders
  • Sickle Cell (HbS) and HbC Disease
  • Spinal Muscular Atrophy
  • Tay-Sachs Disease
  • Usher Syndrome Type IF/PCDH15-Related Disorders
  • Usher Syndrome Type IIIA
  • Usher Syndrome Type IB/MYO7A-Related Disorders
  • Usher Syndrome Type ID/CDH23-Related Disorders
  • Wilson Disease
  • 3-Hydroxy-3-Methylglutaryl-CoA (HMG-CoA) Lyase Deficiency
  • 3-Methylcrotonyl-CoA Carboxylase (3-MCC) Deficiency, MCCC-1/MCCC-2-Related
  • ADA-Related Conditions
  • Alpha-Thalassemia/Alpha-Globin Triplication
  • Argininosuccinic Aciduria
  • Beta-Ketothiolase Deficiency
  • Biotinidase Deficiency
  • Carnitine Palmitoyltransferase II Deficiency
  • Citrin Deficiency
  • Citrullinemia Type 1
  • Congenital Disorder of Glycolysation, PMM-2-Related
  • Galactokinase Deficiency
  • Galactosemia, GALT-Related
  • Glucose-6-Phosphate Dehydrogenase Deficiency
  • Glutaric Acidemia Type 1
  • Holocarboxylase Synthetase Deficiency
  • Homocystinuria, Cobalamin E Type
  • Homocystinuria due to Cystathionine Beta-Synthase Deficiency
  • Isovaleric Acidemia
  • Krabbe Disease
  • Long Chain 3-Hydroxyacyl-CoA Dehydrogenase Deficiency
  • Medium Chain Acyl-CoA Dehydrogenase Deficiency
  • Methylmalonic Acidemia, MMAA/MMAB-Related
  • Methylmalonic Acidemia with Homocystinuria, Cobalamin C Type
  • Methylmalonic Acidemia with Homocystinuria, Cobalamin D Type
  • Mucopolysaccharidosis Type 1 (Hurler Syndrome)
  • Nonsyndromic Hearing Loss
  • Pendred Syndrome
  • Phenylalanine Hydroxylase Deficiency
  • Polycystic Kidney Disease, Autosomal Recessive
  • Primary Carnitine Deficiency
  • Propionic Acidemia, PCCA/PCCB-Related
  • Smith-Lemli-Opitz Syndrome
  • Tyrosinemia Type 1
  • Tyrosinemia Type 2
  • Usher Syndrome Type IIA/USH2A-Related Disorders
  • Very Long-Chain Acyl-CoA Dehydrogenase Deficiency
  • X-Linked Adrenoleukodystrophy

Contact a NxGen Representative

Connect With Us

To review a patient's screening results, login to our HCP portal. To schedule a sample pick-up, click on the link below. To contact our Business Office, please call (855) 776-9436.

Provider Portal Pickup Request
Connect With Us

“Newborn Screening.” NORD (National Organization for Rare Disorders). 26 Jan. 2021.